keyword
MENU ▼
Read by QxMD icon Read
search

Nintedanib

keyword
https://www.readbyqxmd.com/read/28230776/effects-and-side-effects-of-using-sorafenib-and-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#1
REVIEW
Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28138565/3d-pulmospheres-serve-as-a-personalized-and-predictive-multicellular-model-for-assessment-of-antifibrotic-drugs
#2
Ranu Surolia, Fu Jun Li, Zheng Wang, Huashi Li, Gang Liu, Yong Zhou, Tracy Luckhardt, Sejong Bae, Rui-Ming Liu, Sunad Rangarajan, Joao de Andrade, Victor J Thannickal, Veena B Antony
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrotic lung disease characterized by the presence of invasive myofibroblasts in the lung. Currently, there are only two FDA-approved drugs (pirfenidone and nintedanib) for the treatment of IPF. There are no defined criteria to guide specific drug therapy. New methodologies are needed not only to predict personalized drug therapy, but also to screen novel molecules that are on the horizon for treatment of IPF. We have developed a model system that exploits the invasive phenotype of IPF lung tissue...
January 26, 2017: JCI Insight
https://www.readbyqxmd.com/read/28102887/clinical-trial-of-nintedanib-in-patients-with-recurrent-or-metastatic-salivary-gland-cancer-of-the-head-and-neck-a-multicenter-phase-2-study-korean-cancer-study-group-hn14-01
#3
Youjin Kim, Su Jin Lee, Ji Yun Lee, Se-Hoon Lee, Jong-Mu Sun, Keunchil Park, Ho Jung An, Jae Yong Cho, Eun Joo Kang, Ha-Young Lee, Jinsoo Kim, Bhumsuk Keam, Hye Ryun Kim, Kyoung Eun Lee, Moon Young Choi, Ki Hyeong Lee, Myung-Ju Ahn
BACKGROUND: Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all head and neck cancers, but they are histologically heterogeneous. No specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic SGC. Recent studies suggest that vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) play important roles in SGC. Nintedanib is a potent small-molecule, triple-receptor tyrosine kinase inhibitor (VEGFR1, VEGFR2, and VEGFR3; fibroblast growth factor receptor 1 [FGFR1], FGFR2, and FGFR3; and PDGFRα and PDGFRß)...
January 19, 2017: Cancer
https://www.readbyqxmd.com/read/28100551/psychometric-properties-of-the-st-george-s-respiratory-questionnaire-in-patients-with-idiopathic-pulmonary-fibrosis
#4
Jeffrey J Swigris, Dirk Esser, Hilary Wilson, Craig S Conoscenti, Hendrik Schmidt, Wibke Stansen, Nancy Kline Leidy, Kevin K Brown
The St George's Respiratory Questionnaire (SGRQ) has been used to measure health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF).This analysis evaluated the psychometric properties of the SGRQ using data from 428 patients with IPF who participated in a 12-month, randomised, placebo-controlled phase II trial of nintedanib.Internal consistency (Cronbach's α) was 0.91 for SGRQ total and >0.70 for domain scores. Test-retest reliability (intraclass correlation coefficients) was 0...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28096998/treatment-with-nintedanib-for-acute-exacerbation-of-idiopathic-pulmonary-fibrosis
#5
Hiromi Tomioka, Hirohito Takada
There is currently no effective treatment for acute exacerbation of idiopathic pulmonary fibrosis (IPF). We herein report the case of a patient with acute exacerbation of IPF which was treated with nintedanib, an intracellular inhibitor of tyrosine kinases, and showed improvement of the condition. An 84-year-old man with IPF was admitted to our hospital because of dry cough and worsening of dyspnoea within last 1 month. He presented with hypoxemia, and chest high-resolution computed tomography (HRCT) revealed new, bilateral multifocal ground-glass opacities superimposed on the background of lung fibrosis...
March 2017: Respirology Case Reports
https://www.readbyqxmd.com/read/28079978/targeting-coagulation-factor-receptors-protease-activated-receptors-in-idiopathic-pulmonary-fibrosis
#6
REVIEW
C Lin, K Borensztajn, C A Spek
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with a 5-year mortality rate of > 50% and unknown etiology. Treatment options remain limited and, currently, only two drugs are available, i.e. nintedanib and pirfenidone. However, both of these antifibrotic agents only slow down the progression of the disease, and do not remarkably prolong the survival of IPF patients. Hence, the discovery of new therapeutic targets for IPF is crucial. Studies exploring the mechanisms that are involved in IPF have identified several possible targets for therapeutic interventions...
January 12, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28066978/mrecist-to-predict-survival-in-advanced-hcc-analysis-of-two-randomised-phase-ii-trials-comparing-nintedanib-versus-sorafenib
#7
Tim Meyer, Daniel H Palmer, Ann-Lii Cheng, Julia Hocke, Arsène-Bienvenu Loembé, Chia-Jui Yen
BACKGROUND & AIMS: Response Evaluation Criteria in Solid Tumors (RECIST) has been shown to be a poor surrogate for survival benefit with targeted therapy in advanced hepatocellular carcinoma (HCC). METHODS: We investigated whether response evaluated using modified RECIST (mRECIST) predicted overall survival (OS) using data from two Phase II clinical trials. Analyses were conducted on pooled data from 188 patients with advanced HCC treated with nintedanib or sorafenib, of whom 180 were evaluable for response...
January 9, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28045597/a-multi-technique-approach-to-probe-the-interaction-of-a-therapeutic-tyrosine-kinase-inhibitor-nintedanib-and-bovine-serum-albumin
#8
Ali Saber Abdelhameed, Saima Nusrat, Sanjhi Paliwal, Masihuz Zaman, Nida Zaidi, Rizwan Hasan Khan
Drug and protein interaction provides a structural guideline in the rational drug designing and in the synthesis of new and improved drugs with greater efficacy. We have examined here the binding affinity and mechanism of nintedanib (NTB), an anticancer drug (Tyrosine kinase inhibitor) with bovine serum albumin (BSA), under physiological conditions, by spectroscopic techniques. The decrease in Stern-Volmer quenching constants and binding constant with increase in temperature suggests BSA forms a complex with NTB...
January 3, 2017: Preparative Biochemistry & Biotechnology
https://www.readbyqxmd.com/read/28039616/a-cost-effectiveness-analysis-of-nintedanib-in-idiopathic-pulmonary-fibrosis-in-the-uk
#9
C Rinciog, M Watkins, S Chang, T M Maher, C LeReun, D Esser, A Diamantopoulos
BACKGROUND: International guidelines recommend nintedanib (OFEV(®)) as an option for the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: The objective of this study was to assess the cost effectiveness of nintedanib versus pirfenidone, N-acetylcysteine and best supportive care (BSC) for the treatment of IPF from a UK payer's perspective. METHODS: A Markov model was designed to capture the changes in the condition of adults with IPF...
December 31, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/28035951/a-systematic-review-of-the-role-of-dysfunctional-wound-healing-in-the-pathogenesis-and-treatment-of-idiopathic-pulmonary-fibrosis
#10
REVIEW
Alan Betensley, Rabab Sharif, Dimitrios Karamichos
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder showcasing an interaction between genetic predisposition and environmental risks. This usually involves the coaction of a mixture of cell types associated with abnormal wound healing, leading to structural distortion and loss of gas exchange function. IPF bears fatal prognosis due to respiratory failure, revealing a median survival of approximately 2 to 3 years. This review showcases the ongoing progress in understanding the complex pathophysiology of IPF and it highlights the latest potential clinical treatments...
December 26, 2016: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/28012494/hepatotoxicity-of-nintedanib-in-patients-with-idiopathic-pulmonary-fibrosis-a-single-center-experience
#11
Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Hideaki Yamakawa, Masato Morita, Hideya Kitamura, Takashi Ogura
No abstract text is available yet for this article.
January 2017: Respiratory Investigation
https://www.readbyqxmd.com/read/28012486/safety-management-of-treatment-with-nintedanib-in-clinical-practice-of-ipf
#12
EDITORIAL
Arata Azuma
No abstract text is available yet for this article.
January 2017: Respiratory Investigation
https://www.readbyqxmd.com/read/27997064/nintedanib-in-japanese-patients-with-idiopathic-pulmonary-fibrosis-a-subgroup-analysis-of-the-inpulsis%C3%A2-randomized-trials
#13
Arata Azuma, Hiroyuki Taniguchi, Yoshikazu Inoue, Yasuhiro Kondoh, Takashi Ogura, Sakae Homma, Tsuyoshi Fujimoto, Wataru Sakamoto, Yukihiko Sugiyama, Toshihiro Nukiwa
BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in patients with IPF in two replicate trials (INPULSIS®). We examined the efficacy and safety of nintedanib in Japanese patients. METHODS: We conducted pre-specified subgroup analyses of the annual rate of decline in FVC, time to first acute exacerbation (AE), change from baseline in St George's Respiratory Questionnaire (SGRQ) total score and safety using pooled data from the INPULSIS® trials for Japanese patients...
December 20, 2016: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/27997006/-nivolumab-in-second-line-treatment-of-squamous-non-small-cell-lung-cancer
#14
Filippo De Marinis, Antonio Passaro
The treatment of non-small cell lung cancer (NSCLC) is changing dramatically in the last period, considering both non-squamous and squamous disease. In the last five years, the identification of different molecular predictive biomarker (e.g., EGFR, ALK e ROS1) and the utilize of new chemotherapy agents associated or not with antiangiogenics agents (e.g., bevacizumab and nintedanib), allowed the improvement of survival and related responses to these treatments. However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27987591/nintedanib-plus-pemetrexed-versus-placebo-plus-pemetrexed-in-patients-with-relapsed-or-refractory-advanced-non-small-cell-lung-cancer-lume-lung-2-a-randomized-double-blind-phase-iii-trial
#15
Nasser H Hanna, Rolf Kaiser, Richard N Sullivan, Osvaldo Rudy Aren, Myung-Ju Ahn, Beatrice Tiangco, Isabelle Voccia, Joachim von Pawel, Vladimir Kovcin, Jason Agulnik, Birgit Gaschler-Markefski, José Barrueco, Patricia Sikken, Charles Schloss, Joo-Hang Kim
OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27972397/nintedanib-plus-docetaxel-as-second-line-therapy-in-patients-with-non-small-cell-lung-cancer-nsclc-a-network-meta-analysis-vs-new-therapeutic-options
#16
S Popat, A Mellemgaard, M Reck, C Hastedt, Griebsch
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971686/pharmacoeconomic-assessment-of-nintedanib-for-the-treatment-of-idiopathic-pulmonary-fibrosis-in-the-greek-healthcare-system
#17
G Tritaki, K Souliotis, D Bouros, I Papageorgiou, A Diamantopoulos, C Rinciog, U Schmidt
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971558/cost-effectiveness-analysis-of-pirfenidone-for-the-treatment-of-mild-to-moderate-idiopathic-pulmonary-fibrosis-ipf-compared-to-best-supportive-care-and-nintedanib-from-the-italian-nhs-perspective
#18
R Ravasio, M Ferrario, M Pata, P Thuresson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971556/nintedanib-cost-utility-in-idiopathic-pulmonary-fibrosis-in-france
#19
S Bénard, A Schmidt, L Catella, F Porte, M Setton, C Fernandez-Montoya, K Le Lay
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971551/cost-utility-of-nintedanib-vs-pirferidone-in-the-treatment-of-idiopathic-pulmonary-fibrosis-in-spain
#20
S Soulard, C Crespo
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
6846
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"